FDA expedites review of Janssen-Medivir's hep C drug simeprevir

05/14/2013 | Star-Ledger (Newark, N.J.), The

The FDA granted priority-review status to Janssen Research & Development and Medivir's experimental drug simeprevir as a treatment for genotype 1 chronic hepatitis C. Janssen said the FDA is likely to make a final decision this year. Simeprevir, intended to be taken with pegylated interferon and ribavirin, inhibits the protease enzyme that allows the virus to reproduce itself inside cells.

View Full Article in:

Star-Ledger (Newark, N.J.), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC